Reach Us +44-1904-929220
Cancer Biomarkers: The Future Challenge of Cancer | OMICS International | Abstract

Journal of Molecular Biomarkers & Diagnosis
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)


Cancer Biomarkers: The Future Challenge of Cancer

Marco Falasca*

Blizard Institute of Cell and Molecular Science, Centre for Diabetes, Queen Mary University of London, UK

*Corresponding Author:
Marco Falasca
Queen Mary University of London
Barts and The London School of Medicine and Dentistry
Blizard Institute of Cell and Molecular Science
Centre for Diabetes, Inositide Signalling Group, London E1 2AT, UK
E-mail: [email protected]

Received date: March 01, 2012; Accepted date: March 01, 2012; Published date: March 07, 2012

Citation: Falasca M (2012) Cancer Biomarkers: The Future Challenge of Cancer. J Mol Biomark Diagn S2:e001. doi:10.4172/2155-9929.S2-e001

Copyright: © 2012 Falasca M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


In recent years, spectacular advances in understanding of molecular mechanism of cancer progression have revolutionized the way we see the process of malignant transformation and we are waiting for this knowledge to be translate in better treatments for cancer patients. This progress has attracted the interest towards the development of targeted therapies for cancer and creates the basis for the so called “personalized medicine”. However, this advancement has not been paralleled by discoveries in the field of biological indicators, or molecular biomarkers, able to implement the targeted therapies.

Recommended Conferences

15th Global Biomarkers and Clinical Research Summit

Vienna, Austria

2nd International Conference on Biomarkers and Cancer Targets

Capetown, South Africa
Share This Page